Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Zacks Investment Research8/18/2026Positive
GILD
Gilead Sciences IncNASDAQHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$172.25B
P/E Ratio
—
EPS
$-2.67
Beta
0.34
52W High
$155.38
52W Low
$106.44
50-Day MA
$130.18
200-Day MA
$132.45
Dividend Yield
2.33%
Profit Margin
-10.60%
Forward P/E
15.22
PEG Ratio
2.14
About Gilead Sciences Inc
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Fundamentals
| Revenue (TTM) | $30.46B |
| Gross Profit (TTM) | $24.25B |
| EBITDA | $14.60B |
| Operating Margin | 33.70% |
| Return on Equity | -20.70% |
| Return on Assets | 14.10% |
| Revenue/Share (TTM) | $24.51 |
| Book Value | $9.53 |
| Price-to-Book | 14.50 |
| Price-to-Sales (TTM) | 5.66 |
| EV/Revenue | 6.39 |
| EV/EBITDA | 107.95 |
| Quarterly Earnings Growth (YoY) | 54.80% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.12% |
| % Institutions | 92.57% |
Historical Volatility
HV 10-Day
25.73%
HV 20-Day
24.57%
HV 30-Day
30.12%
HV 60-Day
29.53%
HV Rank
71.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($157.41 target)
6
Strong Buy16
Buy7
HoldLatest News
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.
CNBC8/14/2026Negative
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.
Seeking Alpha8/10/2026Positive
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
Zacks Investment Research8/7/2026Positive
Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings
Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and raised guidance. GILD's HIV portfolio, especially Biktarvy and Descovy, continues to drive sales, but revenue concentration poses mid-2030s patent cliff risk. Recent acquisitions inflated Q2 operating losses, yet free cash flow surged to $3.4B, and debt remains manageable relative to cash generation.
Seeking Alpha8/6/2026Positive
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
Zacks Investment Research8/5/2026Positive
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
WSJ8/4/2026Negative
Gilead second-quarter sales rise 8%, beating Wall Street estimates
Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs related to a series of acquisitions.
Reuters8/4/2026Positive
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Zacks Investment Research7/30/2026Positive
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Research7/30/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GILD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026